NGC Update Service: December 30, 2013

National Guideline Clearinghouse (NGC)

December 30, 2013

New This Week

Guideline Summaries

American Society for Radiation Oncology

American Society for Reproductive Medicine

Kidney Disease: Improving Global Outcomes

Program in Evidence-based Care

University of Michigan Health System

Withdrawn Summaries

These summaries have been withdrawn from the NGC Web site because they no longer meet the NGC Inclusion Criteria with respect to date, or because the guideline developer has indicated that they are no longer current. See the Guideline Archive for a complete list of all guidelines that have been withdrawn from the NGC Web site.

Please refer to NGC's FAQ page if you have additional questions about guidelines recently withdrawn.

National Institutes of Health (NIH) State-of-the-Science Panel

  • Prevention of fecal and urinary incontinence in adults.

New York State Department of Health

  • Clinical management of alcohol use and abuse in HIV-infected patients.
  • Drug-drug interactions between HAART, medications used in substance use treatment, and recreational drugs.
  • Mental health disorders among substance-using HIV-infected patients.
  • Smoking cessation in HIV-infected patients.
  • Somatic symptoms: mental health approach and differential diagnosis.
  • Substance use treatment modalities for HIV-infected substance users.


NGC Spotlight

Visit the Guideline Matrix to filter NGC content in a variety of ways.

Revised Inclusion Criteria

NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments.

Conference News

  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisory

  • December 17, 2013: Methylphenidate ADHD Medications: FDA is warning that methylphenidate products, one type of stimulant drug used to treat attention deficit hyperactivity disorder (ADHD), may in rare instances cause prolonged and sometimes painful erections known as priapism. Based on a recent review of methylphenidate products, FDA updated drug labels and patient Medication Guides to include information about the rare but serious risk of priapism. If not treated right away, priapism can lead to permanent damage to the penis.

NGC's Sister Resources